Talking with Your Patients about Latent Tuberculosis (TB) Infection Testing and treating latent TB infection is a critical step to eliminating TB disease in the United States and protecting your community As a trusted source of health information in your community, it’s important to initiate a conversation about latent TB infection and TB disease with your patients since there may be a lack of awareness about or stigma associated with these conditions Here
Treatment for Latent Tuberculosis Infection | Tuberculosis (TB) | CDC People with latent tuberculosis (TB) infection can be treated to prevent TB disease CDC and the National Tuberculosis Coalition of America preferentially recommend short-course, rifamycin-based, 3- or 4-month latent TB infection treatment regimens
About Inactive Tuberculosis | Tuberculosis (TB) | CDC Tuberculosis (TB) germs can live in the body for years without making you sick This is called inactive TB or latent TB infection People with inactive TB do not feel sick, do not have symptoms, and cannot spread TB germs to others Without treatment, inactive TB can develop into active TB disease at any time and make you sick
Latent Syphilis - STI Treatment Guidelines Latent syphilis is defined as syphilis characterized by seroreactivity without other evidence of primary, secondary, or tertiary disease Persons who have latent syphilis and who acquired syphilis during the preceding year are classified as having early latent syphilis (early nonprimary, nonsecondary)
Treating Inactive Tuberculosis | Tuberculosis (TB) | CDC If you have inactive tuberculosis (TB), also called latent TB infection, treating it is the best way to protect you from getting sick with active TB disease Treatment for inactive TB can take three, four, six, or nine months depending on the treatment plan Talk to your health care provider about which treatment is best for you
Latent Tuberculosis Infection Treatment Regimens Treatment regimens for latent TB infection (LTBI) use isoniazid (INH), rifapentine (RPT), or rifampin (RIF) CDC and the National Tuberculosis Controllers Association preferentially recommend short-course, rifamycin-based, 3- or 4-month latent TB infection treatment regimens over 6- or 9-month isoniazid monotherapy